Abstract: A multiple mirror for multiplying a single incident wavefront of electromagnetic radiation into a plurality of outgoing wavefronts, including at least one first mirror, onto which the incident wavefront first falls, and a second mirror, on which the wavefront is last reflected, wherein the mirror planes are superimposed in the direction of movement of the first wavefront. The first mirror is partially transparent to the electromagnetic radiation and the second mirror is fully reflective.

Abstract: A measuring arrangement for non-destructive measurement of an object surface by interferometric measuring methods, wherein light strikes the measuring arrangement as a light beam reflected from the surface, including a diaphragm with an aperture; mirror arrangement with two mirrors having mirror surfaces; a camera lens and camera; wherein the incoming light beam passes the diaphragm and diffracts before hitting the mirror arrangement and splits and deflects into two partial beams, which reach and interfere in the camera; wherein the light beam passes the camera lens in front of the camera in beam direction; and wherein one mirror of the mirror arrangement is rotatable relative to the other; and wherein the camera includes a camera chip with a local sampling frequency and the diaphragm diffracts the incoming light beam as it passes through such that its spatial frequency corresponds at most to the maximum camera chip local sampling frequency during detection.

Abstract: A multiple mirror for multiplying a single incident wavefront of electromagnetic radiation into a plurality of outgoing wavefronts, including at least one first mirror, onto which the incident wavefront first falls, and a second mirror, on which the wavefront is last reflected, wherein the mirror planes are superimposed in the direction of movement of the first wavefront. The first mirror is partially transparent to the electromagnetic radiation and the second mirror is fully reflective.

Abstract: Pharmaceutical formulations comprising monoclonal anti-Factor D antibodies, and their production and use for the treatment of complement-associated ocular diseases are disclosed. The formulations include pre-lyophilized, lyophilized and reconstituted stable liquid formulations of anti-Factor D antibodies, including lampalizumab.